{"id":57008,"date":"2026-02-12T22:21:33","date_gmt":"2026-02-12T14:21:33","guid":{"rendered":"https:\/\/flcube.com\/?p=57008"},"modified":"2026-02-12T22:21:34","modified_gmt":"2026-02-12T14:21:34","slug":"msds-keytruda-wins-fda-approval-for-platinum-resistant-ovarian-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57008","title":{"rendered":"MSD\u2019s Keytruda Wins FDA Approval for Platinum-Resistant Ovarian Cancer"},"content":{"rendered":"\n

Merck & Co.<\/strong> (MSD, NYSE:\u202fMRK<\/a><\/strong>) announced that the U.S. Food and Drug Administration (FDA)<\/strong> has approved Keytruda (pembrolizumab)<\/strong> and Keytruda Qlex (pembrolizumab + berahyaluronidase alfa-pmph)<\/strong> in combination with paclitaxel<\/strong> (\u00b1 bevacizumab) for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma<\/strong> in PD-L1+ (CPS \u22651) adults<\/strong> who have received 1-2 prior systemic regimens<\/strong>. The approval, based on Phase III KEYNOTE-B96 data<\/strong>, marks Keytruda’s entry into platinum-resistant ovarian cancer<\/strong>\u2014a high-unmet-need setting with limited effective options<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Merck, Sharp & Dohme (MSD; NYSE:\u202fMRK)<\/td><\/tr>
Agency<\/strong><\/td>U.S. Food and Drug Administration (FDA)<\/td><\/tr>
Assets<\/strong><\/td>Keytruda (pembrolizumab); Keytruda Qlex (pembrolizumab + hyaluronidase)<\/td><\/tr>
Combination<\/strong><\/td>+ paclitaxel (\u00b1 bevacizumab)<\/td><\/tr>
Indication<\/strong><\/td>Platinum-resistant epithelial ovarian\/fallopian tube\/primary peritoneal carcinoma<\/td><\/tr>
Biomarker<\/strong><\/td>PD-L1+ (CPS \u22651) by FDA-authorized test<\/td><\/tr>
Prior Therapy<\/strong><\/td>1-2 prior systemic treatment regimens<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Evidence \u2013 KEYNOTE-B96 Phase III<\/h2>\n\n\n\n
Endpoint<\/th>Keytruda Regimen vs. Placebo<\/th>Clinical Significance<\/th><\/tr><\/thead>
Progression-Free Survival (PFS)<\/strong><\/td>28% risk reduction<\/strong> (HR=0.72; p=0.0014)<\/td>Primary endpoint met<\/strong>; meaningful disease control<\/td><\/tr>
Overall Survival (OS)<\/strong><\/td>24% risk reduction<\/strong> (HR=0.76; p=0.0053)<\/td>Statistically significant survival benefit<\/strong>; practice-changing<\/td><\/tr>
Patient Population<\/strong><\/td>PD-L1+ (CPS \u22651), platinum-resistant, 1-2 prior lines<\/td>Addressable biomarker-defined population<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Strategic Positioning<\/h2>\n\n\n\n
Factor<\/th>Strategic Analysis<\/th><\/tr><\/thead>
Platinum-Resistant Ovarian Cancer Burden<\/strong><\/td>~80% of advanced ovarian cancer patients<\/strong> develop platinum resistance; median OS <12 months<\/strong>; no standard of care<\/strong> beyond single-agent chemotherapy<\/td><\/tr>
Keytruda Franchise Expansion<\/strong><\/td>30th+ FDA approval<\/strong> for Keytruda; reinforces PD-1 dominance<\/strong> in gynecologic malignancies<\/strong> (endometrial, cervical, now ovarian)<\/td><\/tr>
Keytruda Qlex Differentiation<\/strong><\/td>Subcutaneous formulation<\/strong> (berahyaluronidase) enables office administration<\/strong> vs. IV infusion<\/strong>; convenience advantage<\/strong> in chronic treatment setting<\/strong><\/td><\/tr>
Competitive Landscape<\/strong><\/td>Mirvetuximab soravtansine (ImmunoGen\/ AbbVie)<\/strong> \u2013 FR\u03b1-targeted ADC approved 2022; Keytruda + chemotherapy<\/strong> offers PD-L1-selected, chemotherapy-backbone alternative<\/strong><\/td><\/tr>
Biomarker Strategy<\/strong><\/td>CPS \u22651 cutoff<\/strong> (vs. tumor proportion score) broadens eligible population<\/strong>; companion diagnostic requirement<\/strong> ensures appropriate patient selection<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Development & Commercial Outlook<\/h2>\n\n\n\n
Priority<\/th>Execution Plan<\/th>Timeline<\/th><\/tr><\/thead>
US Launch<\/strong><\/td>Gynecologic oncology specialist education; PD-L1 testing partnership<\/td>Q1-Q2\u202f2026<\/td><\/tr>
Global Expansion<\/strong><\/td>EMA, PMDA, NMPA submissions for platinum-resistant ovarian cancer<\/td>2026-2027<\/td><\/tr>
Combination Optimization<\/strong><\/td>Explore Keytruda + PARP inhibitors (niraparib) or anti-angiogenics in earlier lines<\/td>Investigational<\/td><\/tr>
Biomarker Refinement<\/strong><\/td>CPS \u226510 subset analysis for enhanced efficacy population<\/td>Post-approval<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding Keytruda commercial performance in platinum-resistant ovarian cancer, global regulatory expansion, and competitive dynamics with mirvetuximab soravtansine. Actual results may differ due to reimbursement negotiations, PD-L1 testing adoption rates, and physician preference for chemotherapy-backbone vs. targeted therapy approaches.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Merck & Co. (MSD, NYSE:\u202fMRK) announced that the U.S. Food and Drug Administration (FDA) has…<\/p>\n","protected":false},"author":1,"featured_media":57009,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,120,2675,176,903,18,15],"class_list":["post-57008","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-merck","tag-merck-sharp-dohme","tag-msd","tag-nyse-mrk","tag-pd-1-l1","tag-product-approvals"],"yoast_head":"\nMSD\u2019s Keytruda Wins FDA Approval for Platinum-Resistant Ovarian Cancer - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Merck & Co. (MSD, NYSE:\u202fMRK) announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab + berahyaluronidase alfa-pmph) in combination with paclitaxel (\u00b1 bevacizumab) for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma in PD-L1+ (CPS \u22651) adults who have received 1-2 prior systemic regimens. The approval, based on Phase III KEYNOTE-B96 data, marks Keytruda's entry into platinum-resistant ovarian cancer\u2014a high-unmet-need setting with limited effective options.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=57008\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MSD\u2019s Keytruda Wins FDA Approval for Platinum-Resistant Ovarian Cancer\" \/>\n<meta property=\"og:description\" content=\"Merck & Co. (MSD, NYSE:\u202fMRK) announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab + berahyaluronidase alfa-pmph) in combination with paclitaxel (\u00b1 bevacizumab) for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma in PD-L1+ (CPS \u22651) adults who have received 1-2 prior systemic regimens. The approval, based on Phase III KEYNOTE-B96 data, marks Keytruda's entry into platinum-resistant ovarian cancer\u2014a high-unmet-need setting with limited effective options.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=57008\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-12T14:21:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-12T14:21:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1208.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57008#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57008\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"MSD\u2019s Keytruda Wins FDA Approval for Platinum-Resistant Ovarian Cancer\",\"datePublished\":\"2026-02-12T14:21:33+00:00\",\"dateModified\":\"2026-02-12T14:21:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57008\"},\"wordCount\":391,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57008#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1208.webp\",\"keywords\":[\"Cancer\",\"Merck\",\"Merck Sharp & Dohme\",\"MSD\",\"NYSE: MRK\",\"PD-1\\\/L1\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57008#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57008\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=57008\",\"name\":\"MSD\u2019s Keytruda Wins FDA Approval for Platinum-Resistant Ovarian Cancer - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57008#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57008#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1208.webp\",\"datePublished\":\"2026-02-12T14:21:33+00:00\",\"dateModified\":\"2026-02-12T14:21:34+00:00\",\"description\":\"Merck & Co. (MSD, NYSE:\u202fMRK) announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab + berahyaluronidase alfa-pmph) in combination with paclitaxel (\u00b1 bevacizumab) for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma in PD-L1+ (CPS \u22651) adults who have received 1-2 prior systemic regimens. The approval, based on Phase III KEYNOTE-B96 data, marks Keytruda's entry into platinum-resistant ovarian cancer\u2014a high-unmet-need setting with limited effective options.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57008#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57008\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57008#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1208.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1208.webp\",\"width\":1080,\"height\":608,\"caption\":\"MSD\u2019s Keytruda Wins FDA Approval for Platinum-Resistant Ovarian Cancer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57008#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MSD\u2019s Keytruda Wins FDA Approval for Platinum-Resistant Ovarian Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MSD\u2019s Keytruda Wins FDA Approval for Platinum-Resistant Ovarian Cancer - Insight, China's Pharmaceutical Industry","description":"Merck & Co. (MSD, NYSE:\u202fMRK) announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab + berahyaluronidase alfa-pmph) in combination with paclitaxel (\u00b1 bevacizumab) for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma in PD-L1+ (CPS \u22651) adults who have received 1-2 prior systemic regimens. The approval, based on Phase III KEYNOTE-B96 data, marks Keytruda's entry into platinum-resistant ovarian cancer\u2014a high-unmet-need setting with limited effective options.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=57008","og_locale":"en_US","og_type":"article","og_title":"MSD\u2019s Keytruda Wins FDA Approval for Platinum-Resistant Ovarian Cancer","og_description":"Merck & Co. (MSD, NYSE:\u202fMRK) announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab + berahyaluronidase alfa-pmph) in combination with paclitaxel (\u00b1 bevacizumab) for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma in PD-L1+ (CPS \u22651) adults who have received 1-2 prior systemic regimens. The approval, based on Phase III KEYNOTE-B96 data, marks Keytruda's entry into platinum-resistant ovarian cancer\u2014a high-unmet-need setting with limited effective options.","og_url":"https:\/\/flcube.com\/?p=57008","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-12T14:21:33+00:00","article_modified_time":"2026-02-12T14:21:34+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1208.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=57008#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=57008"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"MSD\u2019s Keytruda Wins FDA Approval for Platinum-Resistant Ovarian Cancer","datePublished":"2026-02-12T14:21:33+00:00","dateModified":"2026-02-12T14:21:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=57008"},"wordCount":391,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=57008#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1208.webp","keywords":["Cancer","Merck","Merck Sharp & Dohme","MSD","NYSE: MRK","PD-1\/L1","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=57008#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=57008","url":"https:\/\/flcube.com\/?p=57008","name":"MSD\u2019s Keytruda Wins FDA Approval for Platinum-Resistant Ovarian Cancer - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=57008#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=57008#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1208.webp","datePublished":"2026-02-12T14:21:33+00:00","dateModified":"2026-02-12T14:21:34+00:00","description":"Merck & Co. (MSD, NYSE:\u202fMRK) announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab + berahyaluronidase alfa-pmph) in combination with paclitaxel (\u00b1 bevacizumab) for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma in PD-L1+ (CPS \u22651) adults who have received 1-2 prior systemic regimens. The approval, based on Phase III KEYNOTE-B96 data, marks Keytruda's entry into platinum-resistant ovarian cancer\u2014a high-unmet-need setting with limited effective options.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=57008#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=57008"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=57008#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1208.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1208.webp","width":1080,"height":608,"caption":"MSD\u2019s Keytruda Wins FDA Approval for Platinum-Resistant Ovarian Cancer"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=57008#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"MSD\u2019s Keytruda Wins FDA Approval for Platinum-Resistant Ovarian Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1208.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57008","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=57008"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57008\/revisions"}],"predecessor-version":[{"id":57010,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57008\/revisions\/57010"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/57009"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=57008"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=57008"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=57008"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}